Dr. LaVallee has more than 25 years of biopharmaceutical and research experience with a broad knowledge in the discovery and development of drugs. She has advanced diagnostics and drugs in oncology, immunology and inflammatory diseases from discovery through approval. Prior to joining Coherus Biosciences as Chief Development Officer, she was Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy (PICI). Before PICI, Dr. LaVallee held executive roles in drug development with Celldex Therapeutics and Kolltan Pharmaceuticals and was part of the team that built the immune-oncology (IO) portfolio at Medimmune/AstraZeneca working on the clinical development and regulatory packages for multiple checkpoint inhibitors and PD-L1 diagnostic. Dr. LaVallee started her career at EntreMed and worked on the initial clinical development of thalidomide and thalidomide analogs. She has a depth of expertise in regulatory strategy to enable science driven development decisions and quality regulatory packages. Dr. LaVallee has spent most of her career working on advancing oncology drugs that can improve the survival and quality of life for cancer patients. She has been key in building successful teams, organizations and collaborations. She is author or co-author of more than 50 publications and abstracts and named in the Top 25 Woman in Biotech in 2023 and Top 20 Woman in Biopharma in 2024 (Endpoints). She received her Ph.D. degree from University of California, Los Angeles and her B.A. degree from UCSB.